ArticleFrontiers in clinical diabetes and healthcare2025
MAFLD in Vietnam: a neglected public health challenge requiring urgent policy action.
Article in Frontiers in clinical diabetes and healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical Heterogeneity, Risk Stratification, and Personalized Care.Clinical and experimental gastroenterology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD) is rapidly emerging as a major public health challenge in Vietnam, driven by rising rates of obesity, type 2 diabetes, and lifestyle changes. Although it contributes significantly to morbidity, mortality, and economic burden, MAFLD remains under-recognized within national health strategies and is largely neglected in non-communicable disease (NCD) frameworks. This narrative review synthesizes epidemiological, clinical, and health systems data on MAFLD in Vietnam, drawing on studies published between 2015 and 2024 alongside international guidelines to evaluate their relevance in the local healthcare setting. The evidence indicates that MAFLD affects more than one-quarter of urban adults and is steadily increasing in rural populations. Barriers to effective management include limited diagnostic capacity, lack of standardized guidelines, insufficient awareness among clinicians, and underdeveloped multidisciplinary care models. Complications are exacerbated by the coexistence of hepatitis B virus infection and the growing burden of cardiovascular comorbidities. Together, these factors heighten disease severity and accelerate progression to cirrhosis and hepatocellular carcinoma. Given these challenges, urgent multisectoral action is needed. We propose a strategic national roadmap that incorporates MAFLD into NCD policy, expands primary care screening using simple non-invasive tools, and invests in health workforce training to improve early detection and risk stratification. Strengthening multidisciplinary collaboration and leveraging digital health technologies can enhance patient engagement and access to care. Finally, regional cooperation and Vietnam's participation in international clinical trials are essential to accelerate innovation and policy response. In conclusion, MAFLD represents a neglected but pressing public health issue in Vietnam. Proactive and coordinated strategies are required to reduce its long-term health and socioeconomic impact and to position Vietnam as a regional leader in addressing metabolic liver disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.